Sponsors
The resolution would boost federal research and support that can improve treatments and outcomes for people with a rare cancer, but it entails modest federal spending and risks concentrating care in specialized centers that could increase access and financial burdens for some patients.
People with chordoma (about 300 U.S. cases/year) would gain increased federal research funding aimed at identifying treatments and potential cures, enabling new clinical trials and expanded treatment options.
Scientists, federal research agencies, and specialized hospitals would receive greater support for studying this rare cancer, strengthening rare-disease programs and helping multidisciplinary centers improve care protocols and patient outcomes.
Patients (especially those in rural or underserved areas) could face increased travel, time, and financial burdens if care concentrates at high-cost tertiary centers where specialized surgical and radiation treatments are available.
Taxpayers could incur additional federal spending to support targeted research and programs, which may require reallocating resources or increasing budgetary costs.
Based on analysis of 2 sections of legislative text.
Formally describes chordoma's rarity, clinical challenges, incidence, and lack of effective drug treatments to raise awareness.
Introduced February 25, 2026 by Hank Johnson · Last progress February 25, 2026
Expresses congressional findings about chordoma, a rare bone cancer of the skull and spine, describing how it behaves, how many people it affects, and the limits of current treatments. The text highlights that chordoma occurs at all ages, causes about 300 new U.S. cases per year and affects over 25,000 people worldwide, and that surgery or radiation can sometimes be curative but recurrence is common and there are no drugs known to reliably cure or control the disease. The resolution mainly raises awareness about the clinical challenges of chordoma—its location near critical nerves and blood vessels, its slow-growing but aggressive behavior, and the lack of effective drug treatments—without creating new programs or funding in the text provided.